USCAP 2024: Routine use of an AI solution for primary diagnosis of prostate biopsies in clinical practice

In a study conducted at UPMC, researchers assessed Ibex Prostate’s performance in primary diagnosis of prostate biopsies, employed in a digital pathology workflow. The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting. The study also demonstrated positive feedback from participating pathologists, showing high satisfaction, particularly with Ibex Prostate’s Gleason scoring, detection of perineural invasion and automated measurement of tissue and tumor length.

The current Ibex offering was formerly known as Galen. Please note that any mention of Galen within these materials refers to a product now known as Ibex.

Share this article:

Subscribe to our newsletter:

By providing my details I agree that my data will be handled in accordance with IBEX Privacy Policy.

How is artificial intelligence rising to the challenge in breast cancer diagnosis?
How ‘game-changing’ AI is helping discover cancer for the first time in UK | ITV News
The AI revolution in cancer diagnostics with Joseph Mossel, CEO of Ibex Medical Analytics
Scroll to Top
IBEX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.